Welcome to our dedicated page for Phio Pharmaceuticals news (Ticker: PHIO), a resource for investors and traders seeking the latest updates and insights on Phio Pharmaceuticals stock.
Phio Pharmaceuticals Corp (NASDAQ: PHIO) is a clinical-stage biotechnology pioneer developing next-generation immuno-oncology therapies using its proprietary INTASYL® RNAi platform. This page provides centralized access to official press releases, clinical trial updates, and strategic partnership announcements related to PHIO's innovative approach to enhancing immune cell function against cancer.
Investors and researchers will find timely updates on PHIO's progress in silencing immune checkpoint targets like PD-1 and TIGIT through its self-delivering siRNA technology. The resource covers key developments including clinical trial milestones, collaborative research findings, and regulatory advancements for therapies like lead candidate PH-762.
Content spans multiple categories essential for tracking biopharmaceutical innovation: clinical trial results, research collaborations with institutions like Gustave Roussy, intellectual property updates, and technology licensing agreements. Each update is sourced directly from company disclosures to ensure reliability.
Bookmark this page for streamlined monitoring of PHIO's advancements in RNAi-based cancer therapeutics. Check regularly for new developments in their mission to overcome tumor-induced immunosuppression through precision gene silencing.
Phio Pharmaceuticals (NASDAQ: PHIO) has secured approximately $2.5 million in gross proceeds through the exercise of outstanding warrants. The agreement involves the exercise of warrants to purchase 928,596 shares of common stock, with 100,000 shares at $2.00 per share and 828,596 shares at a reduced price of $2.485 per share.
In exchange for immediate cash exercise, holders will receive new unregistered warrants for up to 1,857,192 shares at $2.485 per share. These new warrants include two tranches: one with a 24-month term for 1,538,596 shares and another with a 5-year term for 318,596 shares. The offering, managed by H.C. Wainwright & Co., is expected to close around July 28, 2025.
Phio Pharmaceuticals (NASDAQ: PHIO) has announced pathology results for four out of five patients in the fourth cohort of its Phase 1b clinical trial for PH-762. The trial evaluates the intratumoral use of PH-762 in various skin cancers. Key results include a complete pathologic response in one cutaneous squamous cell carcinoma (cSCC) patient and a partial response in a Stage 4 metastatic Merkel cell patient.
Across all four cohorts, 15 patients have been treated with no dose-limiting toxicities or clinically relevant adverse effects. Among 13 cSCC patients, five achieved complete response, one near-complete response, one partial response, and six non-responses. The company is now enrolling what is expected to be the final cohort in the Phase 1b study.
Phio Pharmaceuticals (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company, has secured a contract development and manufacturing agreement with a U.S.-based manufacturer for its lead compound PH-762. The manufacturer will provide analytical and process development services along with cGMP manufacturing of the drug substance.
The agreement marks a crucial step in advancing Phio's intratumoral program for treating cutaneous carcinomas. The company is currently enrolling patients for the 5th and final cohort in its Phase 1b dose escalation study targeting cutaneous squamous cell carcinoma, Merkel cell carcinoma, and melanoma.
Phio Pharmaceuticals (NASDAQ: PHIO) reported positive safety results from the fourth cohort of its Phase 1b clinical trial for PH-762, their lead siRNA compound for skin cancer treatment. The Safety Monitoring Committee recommended advancing to the fifth and expected final dose escalation cohort.
The trial has treated 15 total patients across four cohorts, including 13 with cutaneous squamous cell carcinoma (cSCC), one with metastatic melanoma, and one with Merkel cell carcinoma. Notable results from the first three cohorts showed complete response in 4 of 9 cSCC patients, with additional patients showing near complete or partial responses. No dose-limiting toxicities or serious adverse events were reported.
Phio Pharmaceuticals (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company, announced its participation in Renmark Financial Communications' Virtual Non-Deal Roadshow Series. CEO Robert Bitterman will present on June 30, 2025, at 10:00 am EST, providing updates on the company's INTASYL gene silencing technology and their ongoing clinical trials.
The presentation will focus on their lead compound PH-762 for skin cancer treatment, for which they recently reported positive interim safety and efficacy results in their Phase 1b dose escalation clinical trial. The event will include a live Q&A session, with a replay available on Renmark's website.
Phio Pharmaceuticals (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company, announced its participation in the upcoming Sidoti Micro-Cap Virtual Investor Conference. CEO and Chairman Robert Bitterman will present on May 22, 2025, at 10:00 AM ET, providing updates on the company's proprietary INTASYL gene silencing technology and progress on their ongoing clinical trial of PH-762 for skin cancer treatment.
The presentation will be accessible via webcast, and Bitterman will also host one-on-one meetings with investors during the conference on May 21-22, 2025. Registration for both the presentation and individual meetings is free and available through Sidoti's platform.
Phio Pharmaceuticals (NASDAQ: PHIO) reported positive results from the third cohort of its Phase 1b clinical trial for PH-762, a skin cancer treatment. Two out of three patients with cutaneous squamous cell carcinoma (cSCC) achieved complete pathologic response (100% tumor clearance), while one patient showed non-response. Across all three cohorts, involving 10 patients total (9 cSCC, 1 melanoma), 4 cSCC patients achieved complete response, one showed near-complete response (>90%), and one had partial response (>50%).
The trial evaluates PH-762's safety and tolerability in various skin cancer stages. Notably, no dose-limiting toxicities or significant adverse effects were observed, with the treatment being well-tolerated across all dose cohorts. The fourth cohort is currently enrolling, with trial completion expected in Q3 2025.
Phio Pharmaceuticals (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company, announced its participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series. CEO and Chairman Robert Bitterman will present on May 7, 2025, at 2:00 pm EST, providing updates on the company's proprietary INTASYL gene silencing technology and progress on the ongoing clinical trial of PH-762 for skin cancer treatment. The presentation will include a live Q&A session, with a replay available on Renmark Financial Communications' website.
FAQ
What is the current stock price of Phio Pharmaceuticals (PHIO)?
What is the market cap of Phio Pharmaceuticals (PHIO)?
